According to Figure 12A, TIMP3 alone demonstrated area under curve (AUC) values over 0.5 in more than 15 out of 25 immunotherapy groups, which is comparable to the MSI score, indicating that it is a robust biomarker for cancer prediction. This evidence concerns the gene TIMP3 and cancer.